Tamsulosin detailed information

Jump to navigation Jump to search
Tamsulosin detailed information
Clinical data
Pregnancy
category
Routes of
administration
oral
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability100% (oral)
Metabolismhepatic
Elimination half-life9–13 hours
Excretion76% renal
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC20H28N2O5S
Molar mass408.51

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]



For patient information, click here

Overview

Tamsulosin (rINN) (Template:PronEng) is an α1a-selective alpha blocker used in the symptomatic treatment of benign prostatic hyperplasia (BPH). Tamsulosin was developed by Yamanouchi Pharmaceuticals (now part of Astellas Pharma) and is marketed by various companies under licence, including Boehringer-Ingelheim and CSL. As of 2006, tamsulosin hydrochloride extended-release tablets are marketed under the trade name Flomaxtra. It was formerly marketed as modified-release capsules under the trade name Flomax.

Clinical use

Adverse effects

Two ADRs (Adverse Drug Reactions) have been reported:

  • Immunologic: It contains a sulfa moiety, thus causing typical reactions to sulfa drugs.
  • Ophthalmologic: Patients taking tamsulosin are prone to a complication known as floppy iris syndrome during cataract surgery. Adverse outcomes of the surgery are greatly reduced by the surgeon's prior knowledge of the patient's history with this drug, and thus having the option of alternative techniques. [2]

Tamsulosin has also affected the sexual function in men. Tamsulosin can cause males to experience retrograde ejaculation.

Clinical comparison

Although prostate specific, it does not have the prostate apoptotic effects of other alpha-blockers such as doxazosin and terazosin.

External links

de:Tamsulosin


Template:WikiDoc Sources